ArticleCanadian journal of ophthalmology. Journal canadien d'ophtalmologie2026
Clinical features and outcomes of melanoma involving eyelid and conjunctiva.
Article in Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ruthenium-106 ocular surface brachytherapy for incompletely excised conjunctival melanoma and squamous cell carcinoma.Journal of contemporary brachytherapy · 2026Article
- Ultra-high-frequency ultrasound in the detection of recurrent conjunctival melanoma: A case report.World journal of clinical cases · 2026Article
- Ultra-High-Frequency Ultrasound of Melanoma Excision Scars for Detection of Clinically Occult Local Recurrence: A Single-Center Retrospective Study.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveWe sought to describe the long-term outcomes in patients with melanoma involving the eyelid and conjunctiva.
designA retrospective cohort study.
participantsPatients with biopsy-confirmed melanoma involving the eyelid and conjunctiva.
methodsWe investigated 13 patients from a single academic center with biopsy-confirmed melanoma involving the eyelid and conjunctiva between January 2000 and December 2021. Primary endpoints included local recurrence, metastasis, and death.
resultsPresumed origin of melanoma was conjunctiva in 9 patients (69%), eyelid in 3 patients (23%), and indeterminate in 1 patient (8%). Primary treatment was exenteration in 3 patients (23%), full-thickness resection in 3 patients (23%), Mohs micrographic surgery in 4 patients (31%), and nonsurgical treatment in 3 patients (23%). Four patients (31%) underwent secondary exenteration due to tumour recurrence. Local tumour recurrence occurred in 7 patients (54%) after a mean 43 months (5-167) and metastasis in 4 patients (31%) after mean 29 months (16-46). Five patients (38%) died after a mean of 45 months (16-107) after initial melanoma diagnosis. There were 3 (23%) deaths attributable to melanoma; all had undergone exenteration during their treatment course. In the 7 (54%) patients managed with globe-sparing treatment, all had best-corrected visual acuity of 20/60 or better at last follow-up.
conclusionsIn this cohort, there was a high rate of local recurrence, metastasis, and death, regardless of whether patients received globe sparing or non-globe sparing treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.